NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $3.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.82 0.00 (0.00%) As of 05/22/2026 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Myriad Genetics Stock (NASDAQ:MYGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Myriad Genetics alerts:Sign Up Key Stats Today's Range$3.77▼$3.9550-Day Range$3.55▼$5.1952-Week Range$3.53▼$8.59Volume1.03 million shsAverage Volume1.83 million shsMarket Capitalization$360.80 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingHold Company Overview Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making. Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities. Myriad’s Prolaris® test evaluates prostate cancer aggressiveness by measuring gene expression levels, while its EndoPredict® assay helps predict the likelihood of breast cancer recurrence. The company also provides pharmacogenomic profiling to identify how patients may respond to certain medications, aiding in more precise drug selection and dosing. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has expanded its presence internationally, serving healthcare providers in the United States, Europe, Canada, Australia and select markets in Latin America and Asia. The company operates a network of clinical laboratories and collaborates with academic institutions, biopharmaceutical firms and healthcare systems to advance genomic research and develop novel diagnostic solutions. Under the leadership of President and Chief Executive Officer Mark C. Capone, Myriad continues to invest in research and development to broaden its test menu and drive innovation in precision medicine. The company’s strategic initiatives include expanding direct-to-physician and direct-to-consumer outreach, enhancing its data analytics capabilities and forging partnerships to integrate genetic insights into routine clinical practice.AI Generated. May Contain Errors. Read More Myriad Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreMYGN MarketRank™: Myriad Genetics scored higher than 74% of companies evaluated by MarketBeat, and ranked 173rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.Upside PotentialMyriad Genetics has a consensus price target of $6.50, representing about 70.2% upside from its current price of $3.82.Amount of Analyst CoverageMyriad Genetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.26) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.51% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 8.37.Change versus previous monthShort interest in Myriad Genetics has recently decreased by 4.32%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentMyriad Genetics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Myriad Genetics this week, compared to 4 articles on an average week.Search Interest1 people have searched for MYGN on MarketBeat in the last 30 days. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Myriad Genetics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $722,223.00 in company stock, which represents 0.2002% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $722,223.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.90% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Stock News HeadlinesMyriad Genetics, Inc. (NASDAQ:MYGN) Receives $6.40 Average Target Price from BrokeragesMay 21, 2026 | americanbankingnews.comMyriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing AwarenessMay 15, 2026 | quiverquant.comQYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 25 at 1:00 AM | Profits Run (Ad)Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeMay 15, 2026 | globenewswire.comMyriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 15, 2026 | finance.yahoo.comPaul Bisaro Purchases 7,500 Shares of Myriad Genetics (NASDAQ:MYGN) StockMay 15, 2026 | insidertrades.comGuggenheim Sticks to Their Hold Rating for Myriad Genetics (MYGN)May 14, 2026 | theglobeandmail.comMyriad Genetics (MYGN) price target decreased by 11.49% to 6.35May 14, 2026 | msn.comSee More Headlines MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $6.15 on January 1st, 2026. Since then, MYGN shares have decreased by 37.9% and is now trading at $3.82. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03. Myriad Genetics's quarterly revenue was up 2.3% on a year-over-year basis. Read the conference call transcript. Does Myriad Genetics have any subsidiaries? Myriad Genetics subsidiaries include these companies: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more. Who are Myriad Genetics' major shareholders? Myriad Genetics' top institutional investors include Orbimed Advisors LLC (132.35%), Assenagon Asset Management S.A. (1.53%), Dimensional Fund Advisors LP (0.78%) and Y Intercept Hong Kong Ltd (0.69%). Insiders that own company stock include Paul J Diaz, Samraat S Raha, Richard Bryan Riggsbee, S Louise Phanstiel, Heinrich Dreismann, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings5/05/2026Today5/25/2026AGM 20266/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/10/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MYGN's financial health is in the Red zone, according to TradeSmith. MYGN has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Price Target for Myriad Genetics$6.50 High Price Target$8.50 Low Price Target$5.50 Potential Upside/Downside+70.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$365.90 million Net Margins-48.24% Pretax Margin-48.23% Return on Equity-8.51% Return on Assets-4.48% Debt Debt-to-Equity Ratio0.36 Current Ratio2.40 Quick Ratio2.19 Sales & Book Value Annual Sales$824.50 million Price / Sales0.44 Cash Flow$3.78 per share Price / Cash Flow1.01 Book Value$3.57 per share Price / Book1.07Miscellaneous Outstanding Shares94,450,000Free Float92,653,000Market Cap$360.80 million OptionableOptionable Beta1.81 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MYGN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
